Differential sensitivity of melanoma cell lines with <it>BRAF</it><sup><it>V600E </it></sup>mutation to the specific Raf inhibitor PLX4032
<p>Abstract</p> <p>Blocking oncogenic signaling induced by the <it>BRAF</it><sup>V600E </sup>mutation is a promising approach for melanoma treatment. We tested the anti-tumor effects of a specific inhibitor of Raf protein kinases, PLX4032/RG7204, in melanoma...
Main Authors: | Kehoe Sarah M, Barretina Jordi G, MacConaill Laura E, Sazegar Hooman, Mok Stephen, Hsueh Teli, Guo Deliang, Wang Qi, Nazarian Ramin, Søndergaard Jonas N, Attar Narsis, von Euw Erika, Zuckerman Jonathan E, Chmielowski Bartosz, Comin-Anduix Begoña, Koya Richard C, Mischel Paul S, Lo Roger S, Ribas Antoni |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-04-01
|
Series: | Journal of Translational Medicine |
Online Access: | http://www.translational-medicine.com/content/8/1/39 |
Similar Items
-
Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations
by: Recio Juan A, et al.
Published: (2011-05-01) -
HO-1 Limits the Efficacy of Vemurafenib/PLX4032 in BRAF<sup>V600E</sup> Mutated Melanoma Cells Adapted to Physiological Normoxia or Hypoxia
by: Anna Lisa Furfaro, et al.
Published: (2022-06-01) -
Differential Effects of the Oncogenic BRAF Inhibitor PLX4032 (Vemurafenib) and its Progenitor PLX4720 on ABCB1 Function
by: Martin Michaelis, et al.
Published: (2014-04-01) -
PLX4032 resistance of patient-derived melanoma cells: crucial role of oxidative metabolism
by: Ombretta Garbarino, et al.
Published: (2023-07-01) -
Pharmacodynamic Characterization of the Efficacy Signals Due to Selective BRAF Inhibition with PLX4032 in Malignant Melanoma
by: William D. Tap, et al.
Published: (2010-08-01)